Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials

The phase 2b AMP trials are testing whether the broadly neutralising antibody VRC01 prevents HIV-1 infection in two cohorts: women in sub-Saharan Africa, and men and transgender persons who have sex with men (MSM/TG) in the Americas and Switzerland. We used nonlinear mixed effects modelling of longi...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yunda, Naidoo, Logashvari, Zhang, Lily, Carpp, Lindsay N., Rudnicki, Erika, Randhawa, April, Gonzales, Pedro, McDermott, Adrian, Ledgerwood, Julie, Lorenzo, Margarita M.Gomez, Burns, David, DeCamp, Allan, Juraska, Michal, Mascola, John, Edupuganti, Srilatha, Mgodi, Nyaradzo, Cohen, Myron, Corey, Lawrence, Andrew, Philip, Karuna, Shelly, Gilbert, Peter B., Mngadi, Kathryn, Lazarus, Erica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841500/
https://www.ncbi.nlm.nih.gov/pubmed/33493795
http://dx.doi.org/10.1016/j.ebiom.2020.103203

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841500/
https://www.ncbi.nlm.nih.gov/pubmed/33493795
http://dx.doi.org/10.1016/j.ebiom.2020.103203

Ejemplares similares